Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
Comment: Enfortumab vedotin is an effective therapy and important development for urotherial cancer patients

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 18.06.19
Views: 429
Rating:

Dr Robert Dreicer, Dr Richard Schilsky and Prof Daniel Petrylak

Dr Robert Dreicer (UVA Cancer Center, Charlottesville, USA), Dr Richard Schilsky (Chief Medical Officer, ASCO, USA) and Prof Daniel Petrylak (Yale Cancer Center, New Haven, USA) comment on data, during a press conference at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, from a study looking at the use of the novel targeted treatment enfortumab vedotin in urotherial cancer.

The study enrolled urothelial patients who had been treated with platinum-based chemotherapy and/or checkpoint inhibitors.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation